Wall Street brokerages predict that Immunomedics, Inc. (NASDAQ:IMMU) will report ($0.13) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Immunomedics’ earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.21). Immunomedics reported earnings per share of ($0.22) during the same quarter last year, which suggests a positive year-over-year growth rate of 40.9%. The business is expected to issue its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Immunomedics will report full year earnings of ($0.96) per share for the current fiscal year, with EPS estimates ranging from ($1.07) to ($0.85). For the next year, analysts anticipate that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.96) to $0.50. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Immunomedics.
A number of brokerages have weighed in on IMMU. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Saturday, February 17th. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a research report on Friday, February 9th. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Jefferies Group raised their target price on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.00.
Several institutional investors have recently modified their holdings of the company. NEA Management Company LLC bought a new stake in Immunomedics in the third quarter valued at $38,762,000. Palo Alto Investors LLC boosted its holdings in shares of Immunomedics by 58.6% during the 4th quarter. Palo Alto Investors LLC now owns 4,774,261 shares of the biopharmaceutical company’s stock valued at $77,152,000 after buying an additional 1,763,795 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Immunomedics by 48.5% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 5,225,124 shares of the biopharmaceutical company’s stock valued at $84,438,000 after buying an additional 1,705,624 shares in the last quarter. State Street Corp boosted its holdings in shares of Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock valued at $42,549,000 after buying an additional 1,305,298 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Immunomedics in the 4th quarter worth about $17,941,000. Hedge funds and other institutional investors own 72.69% of the company’s stock.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.